BOSTON--(BUSINESS WIRE)--NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has expanded distribution of the Quell Wearable Pain Relief device to The Grommet, a unique online product launch platform.
“The Quell technology immediately stood out as a unique innovation that would appeal to our customer database. We are proud to feature Quell as the first product innovation from a publicly traded company on the Grommet,” said Ryan DeChance, Discovery Manager.
“The Grommet offers a distinctive opportunity to share the innovation story behind Quell and allow chronic pain sufferers to discover this new treatment modality for chronic pain,” said Frank McGillin, SVP & General Manager, Consumer Health for NeuroMetrix.
Quell is an easy-to-use, over-the-counter wearable technology for chronic pain relief. It utilizes NeuroMetrix's patented OptiTherapy™ technology to provide pain relief. In a recent clinical study, 81 percent of participants reported improvement with chronic pain after using Quell. Quell is available through select healthcare professionals and retailers.
About The Grommet
The Grommet is a product launch website that launched in 2008. They find unique undiscovered products and help them succeed with the goal of leveling the playing field so the best companies can win.
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.